Q&A: A decade on, what’s next for CAR-T therapies?
Pharmaceutical Technology
APRIL 5, 2023
But access to these treatments continues to remain limited due to high price tags and variable availability across regions. But I think we’ve never had more tools than we have now in synthetic biology, genetic engineering, enhanced potency design switches and CRISPR. But there is that significant challenge.
59 
Let's personalize your content